scholarly journals Analyses of clinicopathological, molecular, and prognostic associations of KRAS codon 61 and codon 146 mutations in colorectal cancer: cohort study and literature review

2014 ◽  
Vol 13 (1) ◽  
pp. 135 ◽  
Author(s):  
Yu Imamura ◽  
Paul Lochhead ◽  
Mai Yamauchi ◽  
Aya Kuchiba ◽  
Zhi Qian ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Cohort Study ◽  
Literature Review ◽  
Kras Codon ◽  
Codon 61

scholarly journals Tumour-infiltrating T-cell subsets, molecular changes in colorectal cancer, and prognosis: cohort study and literature review

2010 ◽  
Vol 222 (4) ◽  
pp. 350-366 ◽  
Author(s):  
Katsuhiko Nosho ◽  
Yoshifumi Baba ◽  
Noriko Tanaka ◽  
Kaori Shima ◽  
Marika Hayashi ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Cohort Study ◽  
T Cell ◽  
Literature Review ◽  
T Cell Subsets ◽  
Molecular Changes

scholarly journals Mutation in Kras Codon 13, but not in Codon 12, Correlates with Poor Prognosis in Colorectal Cancer: a Cohort Study

2013 ◽  
Vol 24 ◽  
pp. iv18
Author(s):  
Sakarias Wangefjord ◽  
Nooreldin Zendehrokh ◽  
Björn Nodin ◽  
Magnus Sundström ◽  
Karin Jirström ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Cohort Study ◽  
Poor Prognosis ◽  
Kras Codon

Mutations in NRAS codon 61, KRAS codon 146, and BRAF V600E as prognostic factors in patients who received anti-EGFR antibody for metastatic colorectal cancer.

2012 ◽  
Vol 30 (15_suppl) ◽  
pp. e14126-e14126
Author(s):  
Naoki Takahashi ◽  
Yasuhide Yamada ◽  
Hirokazu Taniguchi ◽  
Kohei Akiyoshi ◽  
Yoshitaka Honma ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Metastatic Colorectal Cancer ◽  
Poor Prognosis ◽  
Tumor Response ◽  
Progression Free Survival ◽  
Braf V600e ◽  
Antibody Treatment ◽  
Kras Codon ◽  
Egfr Antibody ◽  
Codon 61

e14126 Background: Previous studies showed that gene mutations (NRAS, BRAF, PIK3CA) are associated with a poor prognosis or resistance of anti-EGFR antibody in metastatic colorectal cancer (mCRC) patients with wild type (WT) of KRAS codon 12/13 (KRAS-WT). However the significance of these biomarkers has not been clarified. In addition, EGFR immunohistochemistry (IHC) and EGFR gene amplification to evaluate the efficacy of anti-EGFR antibody treatment has not been reported for mCRC. Methods: We evaluated tumor response and survival in patients who received anti-EGFR antibody by mutation analysis of KRAS, NRAS, BRAF, and PIK3CA in KRAS-WT patients with mCRC. Tumor DNA samples are obtained from patients treated in our hospital with anti-EGFR antibody between August 2008 and August 2011. Results: A total of 117 patients were enrolled in this analysis, including 100 KRAS-WT patients. Seventy-one patients (60.7%) were all WT for KRAS, NRAS, BRAF, and PIK3CA, and 46 patients (39.3%) had at least 1 mutation or had insufficient DNA samples to analyze. Mutations of KRAS codon 61 (2 patients), KRAS codon 146 (5), BRAF V600E (2), PIK3CA exon9 (8), NRAS codon 12/13 (2), and NRAS codon 61 (5) were detected. No patients had a mutation of PIK3CA exon 20. Patients with at least 1 mutation had no response. Mutations of NRAS codon 61, KRAS codon 146, and BRAF V600E were associated with a shorter progression free survival (PFS) compared with all WT patients (p=0.049, p=0.004, p=0.036, respectively). Twelve patients (12% of KRAS-WT patients) with a mutation of NRAS codon 61, KRAS codon146, and BRAF V600E had poor prognosis compared with the other KRAS-WT patients (PFS, 6.4 vs 2.0 months, p<0.001; overall survival (OS), 13.7 vs 7.9 months, p=0.012). In all WT patients, moderate to strong EGFR IHC was associated with a better response rate than negative and weak IHC (p=0.046). Conclusions: Mutations of NRAS codon 61, KRAS codon 146, and BRAF V600E could be a strong prognostic factor of anti-EGFR antibody in patients with mCRC. Combination of IHC and DISH of EGFR could identify patients with a tumor response to anti-EGFR antibody in patients that are all WT for KRAS, NRAS, BRAF, and PIK3CA.

scholarly journals Prognostic Role of PIK3CA Mutation in Colorectal Cancer: Cohort Study and Literature Review

2012 ◽  
Vol 18 (8) ◽  
pp. 2257-2268 ◽  
Author(s):  
Xiaoyun Liao ◽  
Teppei Morikawa ◽  
Paul Lochhead ◽  
Yu Imamura ◽  
Aya Kuchiba ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Cohort Study ◽  
Literature Review ◽  
Pik3ca Mutation ◽  
Prognostic Role

scholarly journals Trajectories of sickness absence and disability pension in colorectal cancer: a Swedish cohort study

2020 ◽  
Vol 30 (Supplement_5) ◽  
Author(s):  
L Chen ◽  
K Alexanderson
Keyword(s):  
Colorectal Cancer ◽  
Cohort Study ◽  
Sickness Absence ◽  
Educational Level ◽  
Disability Pension ◽  
Population Based ◽  
Work Situation ◽  
Working Age ◽  
Future Work ◽  
Very High

Abstract Background Working-aged colorectal cancer (CRC) patients have a much better survival nowadays, indicating the importance of their future work situation. We aimed to investigate trajectories of sickness absence and disability pension (SADP) days before and after CRC diagnosis and in references, and risk factors associated with different trajectories. Methods A longitudinal, population-based matched cohort study of 4735 CRC survivors in Sweden aged 19-62 when first diagnosed with CRC in 2008-2011, and 18,230 matched references was conducted, using microdata linked from several nationwide registers. The annual SADP net days for 2 years before through 5 years after diagnosis date were computed. A group-based trajectory model was used to depict SADP trajectories. Associations between trajectory membership, and sociodemographic and clinical variables were tested by chi2 test and multinomial logistic regression. Results Four trajectories of SADP days/year for CRC survivors were identified: “only increase around diagnosis” (52% of all, n = 2481), “slight increase after diagnosis” (27%), “high then decrease moderately after diagnosis” (13%), and “constantly very high” (8%). Educational level (R2=0.022), Charlson's Comorbidity Index (R2=0.029), and prediagnostic mental disorders (R2=0.066) were the strongest factors determining the SADP trajectory groups. In references, three trajectories (”constantly low” (80% of all), “constantly moderate and decrease gradually” (12%), and “very high then decrease overtime” (8%)) were identified. Conclusions Approximately 80% of CRC survivors return to a low level of SADP (0-60 days/year) at 5 years postdiagnosis. Prediagnostic status of mental disorders, somatic comorbidity, and low educational level are good indicators of future high SADP levels for CRC survivors. Key messages Most of working-age colorectal cancer survivors have low levels of sickness absence and disability pension days five years after their diagnosis. Trajectory analyses based on population-based register data can be used as a good approach in understanding future work situation regarding sick leave among working-age cancer survivors.

Sign in / Sign up

Export Citation Format

Share Document